AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns

2 hours ago 1

David Moadel

Tue, April 7, 2026 astatine 8:58 AM CDT 4 min read

JPMorgan maintains its Overweight standing and $260 terms people connected AbbVie (ABBV), calling the pullback a buying accidental arsenic the steadfast sees upside to statement estimates backed by beardown Skyrizi and Rinvoq momentum, contempt near-term headwinds from a $744 cardinal R&D complaint and competitory unit from Johnson & Johnson’s (JNJ) Icotyde.
AbbVie’s caller weakness reflects capitalist nervousness implicit competitory dynamics, but expert statement remains solidly bullish with 22 bargain ratings and zero sells, and the dividend output of 3.18% with a 5.5% rise provides income enactment portion immunology conception maturation (18.3% year-over-year) and neuroscience spot presumption the institution to present connected management’s 2026 guidance if near-term competitory unit doesn’t sharply escalate.
If you're focused connected picking the close stocks and ETFs you whitethorn beryllium missing the bigger picture: status income. That is precisely what The Definitive Guide to Retirement Income was created to solve, and it's escaped today. Read much here

AbbVie (NYSE:ABBV) banal has pulled backmost 12% implicit the past month, sliding to astir $204. JPMorgan isn't moving from that weakness — it's calling it a buying opportunity, maintaining its Overweight standing and $260 terms people connected shares.

Investor sentiment has "become decidedly much negative" owed to competitory dynamics, peculiarly from Johnson & Johnson (NYSE:JNJ). Yet JPMorgan argues that existent stock levels connection an "increasingly charismatic story" heading into AbbVie's Q1 report.

Ticker

Company

Firm

Action

Old Rating

New Rating

Old Target

New Target

ABBV	AbbVie	JPMorgan	Buying Opportunity / Maintains	Overweight	Overweight	N/A	$260

JPMorgan sees upside to statement estimates and AbbVie's ain guidance, adjacent aft the institution revised its full-year adjusted diluted EPS outlook to $13.96 to $14.16 pursuing a $744 cardinal pre-tax IPR&D charge. The steadfast points to Skyrizi and Rinvoq continuing to amusement steadfast maturation arsenic the halfway crushed to enactment constructive.

If you're focused connected picking the close stocks and ETFs you whitethorn beryllium missing the bigger picture: retirement income. That is precisely what The Definitive Guide to Retirement Income was created to solve, and it's escaped today. Read much here

That assurance isn't unfounded. Skyrizi generated $5.01 cardinal successful Q4 2025 revenue, up 32.5% twelvemonth implicit year, portion Rinvoq posted $2.37 billion, up 29.5%. The immunology conception arsenic a full grew 18.3% twelvemonth implicit twelvemonth to $8.63 cardinal successful Q4.

Read Entire Article